**Highlights of This Issue 6333**

**SPECIAL FEATURES**

**CCR Translations**

- **The Role of Protein Kinase CK2 in Glioblastoma Development**
  - Haitao Ji and Zhimin Lu
  - *See related article, p. 6484*

**CCR New Strategies**

- **New Strategies in Radiation Therapy: Exploiting the Full Potential of Protons**
  - Radhe Mohan, Anita Mahajan, and Bruce D. Minsky

**Molecular Pathways**

- **Molecular Pathways: Protein Methyltransferases in Cancer**
  - Robert A. Copeland

**CCR Focus**

- **On Masterpieces and Breast Cancer Research**
  - Susan E. Bates

- **Progress in Breast Cancer: Overview**
  - Carlos L. Arteaga

- **Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer**
  - Aditya Bardia and José Baselga

- **Incorporating Genomics into Breast Cancer Clinical Trials and Care**
  - Adel Tabechy, Cynthia X. Ma, Ron Bose, and Matthew J. Ellis

- **Tackling the Diversity of Triple-Negative Breast Cancer**
  - Nicholas C. Turner and Jorge S. Reis-Filho

- **Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer**
  - Xiang H.-F. Zhang, Mario Giuliani, Meghana V. Trivedi, Rachel Schiff, and C. Kent Osborne

- **Can Immunity to Breast Cancer Eliminate Residual Micrometastases?**
  - Mary L. Disis and Sasha E. Stanton

**HUMAN CANCER BIOLOGY**

- **JMJD2B Promotes Epithelial–Mesenchymal Transition by Cooperating with β-Catenin and Enhances Gastric Cancer Metastasis**
  - Li Zhao, Wenjuan Li, Wen Zang, Zhifang Liu, Xia Xu, Han Yu, Qing Yang, and Jihui Jia

- **Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study**

- **Contrasting Expression Patterns of Histone mRNA and microRNA 760 in Patients with Gastric Cancer**
  - Takeshi Iwaya, Takeo Fukagawa, Yutaka Suzuki, Yunosuke Takahashi, Genta Sawada, Masahisa Ishihashi, Junji Kurashige, Tomoya Sudo, Fumiaki Tanaka, Kohei Shibata, Fumitaka Endo, Hirokatsu Katagiri, Kooru Ishida, Kohei Kume, Satoshi Nishizuka, Hisae Iinuma, Go Wakabayashi, Masaki Mori, Mitsuru Sasako, and Koshi Mimori

- **PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival**
  - Hazel A. Rogers, Cerys Mayne, Rebecca J. Chapman, John-Paul Kilday, Beth Coyle, and Richard G. Grundy

**CNS Metastases in Breast Cancer: Old Challenge, New Frontiers**

- Nancy U. Lin, Laleh Amiri-Kordeestani, Diane Palmieri, David J. Liewehr, and Patricia S. Steeg

**Contents**

The Journal of Clinical and Translational Research  iii  www.aacrjournals.org
CANCER THERAPY: PRECLINICAL

6461 Autotaxin–Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma Shih-Chi Su, Xiaoxiao Hu, Patrick A. Kenney, Megan M. Merrill, Kara N. Babaian, Xin-Rong Zhang, Tapati Maity, Shun-Fa Yang, Xin Lin, and Christopher G. Wood

6473 Cidofovir: A Novel Antitumor Agent for Glioblastoma Piotr Hadaczek, Tomoko Ozawa, Liliana Sorocenau, Yasuyuki Yoshida, Lisa Matlaf, Eric Singer, Estefania Fiallos, C. David James, and Charles S. Cobbs

6484 Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma Ying Zheng, Braden C. McFarland, Denis Drygin, Hao Yu, Susan L. Bellis, Hyunsoo Kim, Markus Bredel, and Etty N. Benveniste


6506 Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models Scott Portwood, Deepika Lal, Yung-Chun Hsu, Rodrigo Vargas, Megan K. Johnson, Meir Wetzler, Charles P. Hart, and Eunice S. Wang

6520 The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low JAM Expression Marion A. Salvador, Julien Vicinski, Olivier Cabaud, Yves Toiron, Pascal Finetti, Emmanuelle Josselin, Hélène Lelièvre, Laurence Kraus-Berthier, Stéphane Depil, François Bertucci, Yves Collette, Daniel Birnbaum, Emmanuelle Charafé-Jauffret, and Christophe Ginestier

IMAGING, DIAGNOSIS, PROGNOSIS

6532 Targeting Src and Tubulin in Mucinous Ovarian Carcinoma Tao Liu, Wei Hu, Heather J. Dalton, Hyun Jin Choi, Jie Huang, Yu Kang, Sunila Pradeep, Takahito Miyake, Jia H. Song, Yunfei Wen, Chunhua Lu, Chad V. Pecot, Justin Bottsford-Miller, Behrouz Zand, Nicholas B. Jennings, Cristina Ivan, Gary E. Gallick, Keith A. Buggerly, David G. Hangauer, Robert L. Coleman, Michael Frumovitz, and Anil K. Sood


CANCER THERAPY: CLINICAL

6572 A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112) Patrick A. Thompson, Rachid Drissi, Jodi A. Muscal, Eshini Panditharatna, Maryam Fouladi, Ashish M. Ingle, Charlotte H. Ahern, Joel M. Reid, Tong Lin, Brenda J. Weigel, and Susan M. Blaney
Effects of Adjuvant Chemoradiotherapy on the Frequency and Function of Regulatory T Cells in Patients with Head and Neck Cancer
Patrick J. Schuler, Malgorzata Harasymczuk, Bastian Schilling, Zenichiro Saze, Laura Strauss, Stephan Lang, Jonas T. Johnson, and Theresa L. Whiteside

ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)
Ronald S. Go, Sandra J. Lee, Donghoon Shin, Steven M. Callister, Dean A. Jobe, Robert M. Conry, Ahmad A. Tarhini, and John M. Kirkwood

Photodynamic Therapy with 3-(1'-Hexyloxyethyl) Pyropheophorbide α for Cancer of the Oral Cavity
Nestor Rigual, Gal Shafirstein, Michele T. Cooper, Heinz Baumann, David A. Bellnier, Ulas Sunar, Erin C. Tracy, Daniel J. Rohrbach, Gregory Wilding, Wei Tan, Maureen Sullivan, Mihai Merzianu, and Barbara W. Henderson

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
Andrew X. Zhu, Richard S. Finn, Mary Mulcahy, Jayne Gurtler, Weijing Sun, Jonathan D. Schwartz, Rita P. Dalal, Adarsh Joshi, Rebecca R. Hozak, Yihuan Xu, Marek Ancukiewicz, Rakesh K. Jain, Francis W. Nugent, Dan G. Duda, and Keith Stuart

A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Ranee Mehra, Fang Zhu, Dong-Hua Yang, Kathy Q. Cai, JoEllen Weaver, Mahendra K. Singh, Anna S. Nikonoa, Erica A. Golemis, Douglas B. Flieder, Harry S. Cooper, Miriam Lango, John A. Ridge, and Barbara Burtness

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows a human U251-MG glioblastoma cell transfected with 100 nM of non-target siRNA. Phalloidin (green) and DAPI (blue) staining shows organized F-actin and cell morphology. For details, see the article by Zheng and colleagues on page 6484 of this issue.